Bavarian Nordic AS News - BV3 | Aktien Tradegate (DE)

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) Recommendation...

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX:...

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today...

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S...

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic A/S – Notice Convening Annual General Meeting COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of...

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older...

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

Bavarian Nordic Publishes Annual Report 2024

Bavarian Nordic Publishes Annual Report 2024 Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two...

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older First chikungunya vaccine...

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine Contract manufacturing agreement marks the first...

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older First chikungunya vaccine approved for persons as...

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025 Travel Health business demonstrated...

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic – Completion of Share Buy-Back Program COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the...

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older First chikungunya vaccine recommended by the...

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Bavarian Nordic AS (BV3)

Professionelle Tools für Privatanleger.

BV3 Nachrichten

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic Publishes Annual Report 2024

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

BV3 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Bavarian Nordic AS (BV3) News

Bavarian Nordic AS (BV3)

Professionelle Tools für Privatanleger.

BV3 Nachrichten

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic Publishes Annual Report 2024

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

BV3 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen